Coronavirus vaccine developer CanSino offers shares in China’s second-most expensive initial public offering

CanSino Biologics, the Tianjin-based pharmaceutical producer that is conducting human trials on its coronavirus vaccine, has set the second-highest price in its secondary listing on the Shanghai Star Market.The company priced its A shares at 209.71 yuan (US$29.96) each, opening them for subscription on Friday, CanSino said in an exchange filing. Its stock jumped by as much as 11.4 per cent on the Hong Kong stock exchange to an intraday record of HK$274 after the news.The offer price for CanSino…

Read the original article at South China Morning Post